Navigation Links
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Date:5/18/2009

WILMINGTON, Del., May 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that all wholesale ordering restrictions in place for TOPROL-XL(R) (metoprolol succinate) extended release tablets have been removed and that supply levels of TOPROL-XL are approaching near usual levels at all points in the distribution chain.

AstraZeneca has been diligently working to help ensure adequate market supply of TOPROL-XL and the authorized generic metoprolol succinate following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate in late 2008 and early 2009.

"After the two generic manufacturers stopped supplying the market, it was critical that we quickly boost our production to increase the supply available for patients," said Kathy Monday, Vice President at AstraZeneca.

To help ensure equitable distribution of TOPROL-XL, AstraZeneca had initially instituted a short-term order management system to wholesalers. That system has now been lifted as AstraZeneca is now manufacturing and distributing enough TOPROL-XL and authorized generic metoprolol succinate to meet historical demand levels. The authorized generic is distributed and marketed by Par Pharmaceutical.

"TOPROL-XL and metoprolol succinate should now be available for patients in all regions across the country," said Monday.

AstraZeneca has been manufacturing TOPROL-XL for the US market since 1992 and is making significant investments in order to help ensure that supply is available to meet the needs of patients in the US, while not impacting supply available to patients in the rest of the world.

TOPROL-XL and metoprolol succinate patients should always consult with their health care professional if they have concerns about their medication. Pati
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
2. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
3. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
4. AstraZenecas David Brennan Elected PhRMA Board Chairman
5. Video: Astrazeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
6. AstraZeneca Applauds Appointment of New FDA Commissioner
7. AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
8. Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
9. AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008
10. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
11. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ndall Hunt authors earned the 2009 Gifted Child Qu...onal Association for Gifted Children’s annua... Dubuque, IA (PRWEB) Decemb...d the 2009 Gifted Child Quarterly Paper of the Yea...ted Children’s annual conference in St. Loui...
(Date:12/2/2009)...re/ -- In response to rising suicide and divorce r...rofit ministry dedicated to supporting marriages a...® marriage conference at a significant disco...13 at the Grand Hyatt Atlanta in Buckhead (3300 Pe...iage getaway aimed at strengthening healthy marria...
(Date:12/2/2009)...paign Features Small Business Owners Detailing How... Jobs ,, WASHINGTON, Dec. 2 /PRNewswire-USNews...led for Thursday, Keeping Small Business Healthy, ...unced a new $1 million 4 state TV ad campaign targ...h care legislation on small business owners and ho...
(Date:12/2/2009)...RNewswire-USNewswire/ -- At a recently concluded f...delegates came together to outline the future of m...he necessary thrust. Organized by the Medical Tour...tion.com , the high-powered congregation of senior...nities and requests for assistance in medical tour...
(Date:12/2/2009)..., Dec. 2 Lockton Benefit Group i...cal view on proposed health reform legislation wor...newscom.com/cgi-bin/prnh/20090415/CG99351LOGO ) ,... the legislation, according to Ed Fensholt and Mar...Compliance Services Division and Lockton,s Healt...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care 2Health News:With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care 3Health News:With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care 4Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2
...aid that older hospital patients with delirium run...e condition. Researchers suggested there's a need ...nt can be made and to investigate interventions th...onal delirium - described as possible hallucinatio...
... may be only a dash and sprinkel away: Researchers...d that herbs, in addition to making food tastier, ...rovide potential anticancer benefits when suppleme...dings appear in the Journal of Agricultural and Fo...
...a recent study a device was found using new techno... of screening people for potential stroke involves...arotid arteries that serve the brain.// Resear...e, this was used to take two different images in a...
...hat protects children against measles, mumps and r... growing list of scarce drugs, with shortfalls cau... pharmaceutical companies choosing to stop making ...neumococcal vaccine used to prevent bacterial meni...
...s are confirming in laboratory studies that one of...ted from beehives--may inhibit the development of ...inas, Brazil, found that propolis// considerably r...promote the binding of cariogenic bacteria to teet...
...now say that a region in the brain responsible for...pathise for others and help the needy. Neuroscient... brain regions involved in learning by imitation./...inguish the self from others.The research, done by...
Other Medicine News:Health News:Herbs: rich soure of antioxidants 2Health News:The brain wave 2
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...eported that its,subsidiary Jiangsu Yanshen Biolog...) has suspended production of all its products in ...
(Date:12/2/2009)..., , EAST HANOVER, N.J., Dec. 2 /PRN..., including a late-breaking presentation on Tasign...hronic myeloid leukemia, demonstrate the strength ... the care of patients. ,, The new data, at the...Meeting and Exposition, highlight the company,s cu...
(Date:12/1/2009)..., , TEMECULA, Calif., Dec. 1 /PRNewswire-Fi... Bulletin Board: PSTX) announced today that it has...of Chief Financial Officer, Treasurer and Corporat...cting CFO since 2008. Prior to joining Patient Sa...nt Finance, Chief Financial Officer, Treasurer and...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Humans Can Develop Bat Like Echolocation 51093 1Humans Can Develop Bat Like Echolocation 51093 2Communicating science to decision makers 51089 1Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 1Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 2
...SS WIRE)--Jun 5, 2007 - Javelin,Pharmaceuticals, I...ucts for pain control, today announced that its Ph...n Pain Medicine, the,official journal of The Ameri...d, "Analgesic Efficacy and Safety of,Morphine-Chit...evere Pain Following Orthopedic Surgery", was rece...
...ta Presented at the , 2007 American Society of Cli...) Activity in Older Patients with AML and in,Refra...on of the molecular interaction of Aloxi(R),with ,...rvival Analysis of Glioblastoma Patients,Treated ,...cribed-- , --Survival Analysis of Irofulven in Sec...
Other Medicine Technology:Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 2Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 10
Right Dr. White Carina Hook
SHERIDAN LASER-TRACH Endotracheal Tubes
SHERIDAN LAR-A-JECT® Reinforced Laryngectomy Tubes
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes
Medicine Products: